We would like to ensure that you are still receiving content that you find useful – please confirm that you would like to continue to receive ILO newsletters.
05 June 2019
On 16 April 2019 Health Canada released a notice inviting drug submissions containing high-quality, real-world evidence along with a document providing principles for the collection and evaluation of real-world evidence.
Submissions containing real-world evidence are encouraged:
Sponsors must clearly identify that a submission contains real-world evidence. When real-world evidence is used as pivotal evidence, a sponsor must also:
A further joint document regarding the use of real-world evidence is expected to be published later in 2019 by Health Canada, the Canadian Agency for Drugs and Technologies in Health and the Institut national d'excellence en santé et en services sociaux.
For further information on this topic please contact Brandon Heard at Smart & Biggar/Fetherstonhaugh by telephone (+1 416 593 5514) or email (email@example.com). The Smart & Biggar/Fetherstonhaugh website can be accessed at www.smart-biggar.ca.
The materials contained on this website are for general information purposes only and are subject to the disclaimer.
ILO is a premium online legal update service for major companies and law firms worldwide. In-house corporate counsel and other users of legal services, as well as law firm partners, qualify for a free subscription.